# Ipamorelin FAQ: Risks, Side Effects, Half-Life, and the Evidence > Ipamorelin FAQ: the risks, side effects, cortisol/prolactin profile, half-life, and whether it works — direct, cited answers from the published record. ## What are the risks of ipamorelin? The main risk is the unknown: no long-term human safety study exists, and the one efficacy RCT (n=114, ≤7-day IV) showed no specific safety signal but also missed its endpoint [3]. Documented concerns are class-level and mechanistic — GH-axis effects on glucose and fluid, a theoretical IGF-1/cancer concern [4], and a cardiotoxicity signal from a 28-day rat study of a related receptor agonist [6]. ## What are the downsides of ipamorelin? The biggest downside is that it has not been shown to work for anything in humans — its only Phase 2 trial missed its primary endpoint (25.3 h vs 32.6 h, p=0.15) [3]. Other downsides: no approved status, no long-term safety data [3], unverified purity of research-grade material, and a WADA S2 ban in sport. Reported nuisance effects include flushing and mild puffiness, anecdotally. ## Does ipamorelin cause cancer? No ipamorelin study has shown it causes cancer, and none has tested the question in humans. The concern is theoretical and mechanistic: GH stimulates IGF-1, a mitogen that promotes cell proliferation [1][4], so chronically raising GH could in theory accelerate growth in a pre-existing tumor. There is no observed oncologic event in any ipamorelin study to confirm or refute this — the long-term human data simply do not exist [3]. ## What are the side effects of CJC-1295 and ipamorelin? No controlled human trial has characterized side effects of the combination [3]. Commonly reported (anecdotal) effects include facial flushing, mild water retention, tingling in the extremities, increased hunger, lightheadedness, and injection-site irritation. Mechanistic cautions apply to the ipamorelin component — glucose effects [13], appetite stimulation [15], and a class cardiotoxicity signal [6] — none resolved in humans. ## Does ipamorelin affect cortisol or prolactin? Minimally — that is its defining feature. In its founding characterization, ipamorelin released GH potently (swine ED50 2.3 nmol/kg) yet did not raise ACTH or cortisol above the GHRH baseline even at more than 200× its GH ED50 [1]. This cortisol- and prolactin-sparing selectivity is what distinguished it from earlier growth-hormone-releasing peptides like GHRP-6 and GHRP-2 [1]. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary to release a pulse of growth hormone, without meaningfully raising cortisol or prolactin [1]. Developed by Novo Nordisk in the 1990s, it was the first highly selective growth hormone secretagogue and has never been approved as a drug [3]. ## What does ipamorelin do for you? In studies, ipamorelin releases a discrete pulse of growth hormone via the ghrelin receptor [1] and, in rodents, increased longitudinal bone growth and body weight [4][7]. In people, the one efficacy trial (for bowel-function recovery) did not work [3]. Community users anecdotally report better sleep and recovery, but these are unverified reports, not demonstrated human outcomes. ## What is ipamorelin peptide? "Ipamorelin peptide" is the same compound: a five-amino-acid (pentapeptide) growth hormone secretagogue, formula C₃₈H₄₉N₉O₅, ~711.9 Da, CAS 170851-70-4 [1]. It is wholly synthetic, derived from GHRP-1, and acts as a selective ghrelin-receptor (GHS-R1a) agonist [1]. It is not an endogenous human peptide and not an approved medicine [3]. ## Does ipamorelin reduce belly fat? No human trial has tested ipamorelin for belly fat. The closest in-vivo data is a 2024 ferret study where ipamorelin (1–3 mg/kg IP) inhibited cisplatin-induced weight loss by about 24% but had no anti-emetic effect [5] — a weight-preservation effect, not fat loss. Community users occasionally report a gradual leaner look over weeks, but that is anecdotal and confounded by diet and training. ## Why is ipamorelin being discontinued? Ipamorelin was never an approved product, so there is nothing to "discontinue" in that sense — its clinical development stopped because its only Phase 2 trial (postoperative ileus) missed its primary endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, tightening compounding-pharmacy access. ## What does CJC-1295 and ipamorelin do? They release growth hormone through two different receptors — CJC-1295 via the GHRH receptor, ipamorelin via the ghrelin receptor — and can act synergistically [9]. A 2026 review found the combination improved muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while stressing evidence is limited to animal studies [18]. No human outcome trial of the combination exists [3]. ## Does ipamorelin increase IGF-1? Not consistently in short studies. Ipamorelin releases GH, which can raise hepatic IGF-1 over time, but in a 15-day rat bone-growth study total IGF-1 did not change despite dose-dependent bone growth — pointing to a partly local, GH-pulse-driven effect [4]. In a diabetic-mouse model, the IGF-1 response was actually absent alongside hepatic GH-receptor resistance [8]. So IGF-1 elevation is context-dependent, not guaranteed. ## How does CJC-1295 ipamorelin work? CJC-1295 (a GHRH analog) raises GH through the GHRH receptor's cAMP pathway, while ipamorelin activates the ghrelin receptor (GHS-R1a) through the calcium pathway [1]. Because they hit different doors, combining them can produce GH release greater than either alone — true synergism shown for a GHRP plus GHRH in humans (P=0.001) [9]. The synergy is the mechanistic rationale for the pairing. ## How much CJC-1295 ipamorelin should I take? No published human trial supports a dose for the combination, and this site does not provide one. Its evidence is single-agent pharmacology plus animal work; a 2026 review noting a muscle effect in mice explicitly said evidence is limited to animal studies [18]. Community subcutaneous regimens have no peer-reviewed human dosing basis and are anecdotal, not recommended [3]. ## Does CJC-1295 ipamorelin work? For raising GH acutely, yes — GHRP + GHRH combinations produce synergistic GH release and prolonged GHRP-6 infusion more than doubled integrated GH in men [10]. For clinical outcomes like fat loss or muscle in humans, it has not been demonstrated in controlled trials [3]. The 2026 evidence remains animal-only for the combination's functional effect [18]. ## How to reconstitute CJC-1295 ipamorelin 5mg? As research handling, not a use instruction: ipamorelin is supplied as a lyophilized (freeze-dried) powder and, in the research-supply literature, reconstituted with bacteriostatic water, then kept refrigerated because peptides degrade with heat and freeze-thaw. The "5mg" is a supplier vial-labeling convention, not a validated dose. No human dosing is provided, and the human PK basis comes from IV studies [2]. ## How long does ipamorelin stay in your system? About 2 hours terminal half-life by vein in healthy volunteers, with the GH pulse peaking around 40 minutes after dosing [2]. After roughly four to five half-lives (≈8–10 hours) it is effectively cleared. Note that anti-doping detection windows can outlast the plasma half-life — a short half-life does not mean a short detection window. Subcutaneous human kinetics are uncharacterized [3]. ## Does ipamorelin make you hungry? It can, by mechanism — ipamorelin works on the ghrelin ("hunger hormone") receptor, and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding as a class [15]. Some community users report an uptick in appetite after injecting (anecdotal), generally described as milder than with GHRP-6. An ipamorelin-derived oral analog also produced body-weight gain over 14 days in rats [7]. ## Will I gain weight on ipamorelin? Possibly via two routes the data show: increased appetite (ghrelin-receptor mechanism) [15] and a GH-independent stimulation of adiposity and leptin seen in mice after two weeks of dosing [14]. In rats, an ipamorelin-derived analog produced significant body-weight gain over 14 days [7]. No human body-weight trial of ipamorelin exists [3], so individual outcomes are uncharacterized and confounded by diet. ## Does ipamorelin increase appetite? Yes, by its mechanism. As a ghrelin-receptor (GHS-R1a) agonist, ipamorelin engages the same receptor the hunger hormone ghrelin uses, and central administration of ghrelin and GH secretagogues activates hypothalamic appetite centers and induces feeding [15]. Community accounts describe increased hunger after injecting as an occasional, usually mild effect (anecdotal). The class signal is well established even though ipamorelin-specific human appetite data are absent. ## What does ipamorelin peptide do? It selectively triggers a pulse of growth hormone by activating the ghrelin receptor (GHS-R1a) on the pituitary, without meaningfully raising cortisol or prolactin [1]. In animals it increased bone growth and body weight [4][7]; in humans its one efficacy trial failed [3]. It is a research peptide, not an approved drug, and produces a single GH pulse peaking ~40 minutes post-dose [2]. ## How long does it take for ipamorelin to work? The hormonal effect is fast: the growth-hormone pulse peaks about 40 minutes (0.67 h) after an IV dose [2]. Any *felt* effects people describe — like sleep changes — are reported anecdotally to appear over one to two weeks of a routine, but these are unverified community reports, not measured outcomes. The peptide itself clears within hours, with a ~2-hour terminal half-life [2]. --- A tolerability-first read of the ipamorelin record — the failed Phase 2 endpoint, the two-hour half-life, and the class cardiotoxicity signal logged before anything flattering, every figure carried back to the study that measured it; a reference console, never a clinic, a prescriber, or a store.